Nutriband Announces Data Supporting Need for Safer Abuse-Deterrent Transdermal Patches Presented at 2024 American Academy of Pain Medicine Annual MeetingAccesswire • 03/25/24
Prescription Transdermal Patch Abuse and Accidental Pediatric Exposure Remains a Serious Problem in the United States - Surveillance Data to Be Presented at 2024 American Academy of Pain Medicine Annual MeetingAccesswire • 03/04/24
Nutriband Inc. to Present at The Microcap Conference Atlantic City January 30th through February 1stAccesswire • 01/29/24
Nutriband Inc. Expands its AI Kinesiology Tape Portfolio with the Launch of AI Tape Heating and CoolingAccesswire • 11/28/23
Nutriband Inc. Signs Supplier Agreement With KT Tape, the World Leader in Kinesiology TapeAccesswire • 11/08/23
Nutriband's Aversa(TM) Buprenoprhine May Reach Peak Annual Sales of $70-130 Million Based on Market Assessment by Leading Healthcare Consulting FirmAccesswire • 10/11/23
Nutriband Announces Issuance of U.S. Patent for Transdermal Abuse Deterrent TechnologyAccesswire • 09/20/23
Nutriband Inc. Reports Second Quarter 2023 Financial Results and Provides Business UpdateAccesswire • 09/11/23
Nutriband Increases Existing Credit Line to $5 Million USD for the Development of its AVERSA(TM) Platform Towards FDA SubmissionAccesswire • 07/14/23
Nutriband Receives Notice of Allowance for U.S. Patent Covering Transdermal Abuse Deterrent TechnologyAccesswire • 06/23/23
Nutriband Inc. to Present at the Planet MicroCap Showcase: VEGAS 2023 on Wednesday, April 26, 2023Accesswire • 04/19/23
Nutriband Secures $2 Million Line of Credit Financing Facility to be Used for Commercialization of AVERSA(TM) Abuse-Deterrent Transdermal TechnologyAccesswire • 03/28/23
Nutriband COO Alan Smith Ph.D. Selected for FDA Center for Research on Complex Generics Stakeholder Expert CommitteeAccesswire • 03/02/23
Nutriband Inc. to File for Product Distribution Permit in South America with Ecuador's Health RegisterAccesswire • 02/15/23